Tag Archives: G8

Dexcom Q2 ’26 Earnings; Novo Ziltivekimab CVOT Miss; CSPC Initiates China-Based QM Dual Agonist Study

Three cardiometabolic-related news items have been observed: Dexcom hosted its Q2 ’26 earnings call (view press release; view slides); Novo’s Ph3 ZEUS trial evaluating ziltivekimab missed the primary CV endpoint (view press release); and CSPC initiated a Ph1 study evaluating its QM GLP-1/GIP dual agonist (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Dexcom 2026 Investor Day; “Self-Adapting” G8 CGM to Launch Late-2027

Dexcom hosted its 2026 Investor Day and provided updates across its diabetes business, including the ongoing launch of the G7 15-day, its next-gen G8 CGM, as well as a new dual glucose-potassium sensor (view slides). Following the call, Dexcom’s stock is up ~6% today. In conjunction with the Investor Day, Dexcom also announced updates to its governance structure, including the planned addition of two new independent board members (view press release). Below are highlights and insights from the investor event.

This content is for Read Less members only.
Already a member? Log in here

JPM 2026 Day 1: DXCM, ARWR, NVS, ALNY, PFE, SNY, CYTK, MDT, MDGL, REGN; Skye 2026 Corporate Outlook; BioAge NLRP3i Ph1 Data; Kailera Ph3 KaiNETIC Program Update

On the first day of JPM 2026, FENIX has provided coverage of presentations by major CVRM companies, including Dexcom, Arrowhead, Novartis, Alnylam, Pfizer, Sanofi, Cytokinetics, Medtronic, Madrigal, and Regeneron. Additionally, three cardiometabolic-related news items have been observed: Skye Biosciences released its 2026 corporate outlook (view press release); BioAge Labs announced updated Ph1 data of its NLRP3i for CV risk reduction (view press release); and Kailera announced it randomized the first patients in its Ph3 KaiNETIC program (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Dexcom Q4 ’24 Earnings

Dexcom hosted its Q4 ‘24 earnings call (press release; slides) and provided updates across its business. Importantly, the company provided additional details into its next-gen G8 sensor platform. Below, FENIX provides highlights and insights from the call.

This content is for Read Less members only.
Already a member? Log in here